CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

Phase 1

CART123 & RuxolitinibCART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Sponsor:

Stephan Grupp MD PhD

Code:

NCT07464951

Conditions

Acute Myeloid Leukemia (AML)

Eligibility Criteria

Sex: All

Age: 0 - 29

Healthy Volunteers: Not accepted

Interventions

Anti-CD123 LV redirected T cells (CART123)

Ruxolitinib (JAKAVI®)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-09. This information was provided to ClinicalTrials.gov by Stephan Grupp MD PhD on 2026-05-27.